Siste nytt - Ypsomed

Ypsomed announces details of capital increase

14.06.2022 - 07:00 Ad hoc announcement pursuant to Art. 53 LR

Burgdorf – The Board of Directors of Ypsomed (SIX: YPSN) decided in its meeting on Monday, 13 June 2022, to carry out a capital increase from authorised capital created by the resolution of the Annual General Meeting on Wednesday, 30 June 2021, in the amount of a maximum of 1 million fully paid registered shares with a nominal value of CHF 14.15 each. The new shares will be offered to the existing shareholders at market conditions with a discount expected to be between 2% to 3%, while maintaining the subscription rights. It is envisaged to sell the unsubscribed shares in a free placement. There will be no trading of subscription rights. The new shares will be eligible for the dividend payment of 06 July 2022. Zürcher Kantonalbank is the Sole Global Coordinator of this capital increase.

Les mer … Ypsomed announces details of capital increase

Ypsomed increases sales by 15.2% and triples its operating profit

25.05.2022 - 07:00 Ad hoc announcement pursuant to Art. 53 LR

Burgdorf – Ypsomed (SIX: YPSN) generated a growth in sales of 15.2% in the financial year 2021/22 compared to the previous year and achieved a consolidated turnover of CHF 464.8 million (previous year: CHF 403.7 million). On its continued growth path, the company trebled its operating result (EBIT) to CHF 28.6 million versus the previous year (previous year: CHF 9.3 million). Compared with the previous year, the net profit increased nearly fourfold to CHF 23.1 million (previous year: CHF 5.8 million). In addition, Ypsomed is planning a capital increase to support the targeted growth.

Les mer … Ypsomed increases sales by 15.2% and triples its operating profit

Changes in the Board of Directors at Ypsomed

18.05.2022 - 07:00 Ad hoc announcement pursuant to Art. 53 LR

Burgdorf – Ypsomed (SIX: YPSN) announces changes to the Board of Directors. The founder and Chairman of the Board of Directors of the Ypsomed Group Dr. h.c. Willy Michel will not stand for re-election as Chairman and member of the Board of Directors at the upcoming Annual General Meeting on 29 June 2022. The Board of Directors proposes to the Annual General Meeting 2022 to elect the current member of the Board of Directors, Gilbert Achermann as new Chairman. Simon Michel will be nominated for election as a new member of the Board of Directors.

Les mer … Changes in the Board of Directors at Ypsomed

Ypsomed, Abbott and CamDiab unveil new automated insulin delivery partnership for people with diabetes

27.04.2022 - 06:00 Press Releases Ypsomed Group

Burgdorf – Ypsomed, Abbott and CamDiab will work to accelerate the development of an automated insulin delivery system for people living with diabetes. The system is being designed to include Abbott’s FreeStyle Libre 3 sensor, CamDiab’s CamAPS FX algorithm, and Ypsomed’s mylife YpsoPump. The partnership demonstrates the companies’ collective desire to drive integrated solutions to help people with diabetes better manage their condition and improve health outcomes.

Topics:

Innovation & Digital Health

Les mer … Ypsomed, Abbott and CamDiab unveil new automated insulin delivery partnership for people with diabetes

Ypsomed partners with CamDiab Ltd to drive on smartphone based adaptive automated insulin delivery (AID)

22.03.2022 - 07:00 Press Releases Ypsomed Group

Burgdorf – Ypsomed partners with CamDiab Ltd, the developer of CamAPS FX, an app to manage glucose levels via insulin pumps using an adaptive, hybrid closed-loop approach. During the first half of 2022, this easy-to-use loop solution will be launched for the mylife YpsoPump system, starting in selected major countries in Europe and followed by other territories in the course of the year. Patients can then connect the mylife YpsoPump system to the mylife CamAPS FX Android mobile application and are enabled to algorithm-based insulin delivery support including bolus from the personal smartphone.